These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 26568589

  • 1. Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
    Steiman AJ, Gladman DD, Ibañez D, Noamani B, Landolt-Marticorena C, Urowitz MB, Wither JE.
    J Rheumatol; 2015 Dec; 42(12):2318-26. PubMed ID: 26568589
    [Abstract] [Full Text] [Related]

  • 2. Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
    Steiman AJ, Urowitz MB, Ibañez D, Li TT, Gladman DD, Wither J.
    J Rheumatol; 2015 May; 42(5):810-6. PubMed ID: 25729033
    [Abstract] [Full Text] [Related]

  • 3. Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study.
    Huang H, Mu L, Zhang Z, Gao D, Hao Y, Zhou W.
    Arthritis Res Ther; 2021 Oct 29; 23(1):275. PubMed ID: 34715915
    [Abstract] [Full Text] [Related]

  • 4. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.
    Steiman AJ, Gladman DD, Ibañez D, Urowitz MB.
    Arthritis Care Res (Hoboken); 2012 Apr 29; 64(4):511-8. PubMed ID: 22162433
    [Abstract] [Full Text] [Related]

  • 5. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome.
    Steiman AJ, Gladman DD, Ibañez D, Urowitz MB.
    J Rheumatol; 2010 Sep 29; 37(9):1822-7. PubMed ID: 20595281
    [Abstract] [Full Text] [Related]

  • 6. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.
    Ng KP, Manson JJ, Rahman A, Isenberg DA.
    Arthritis Rheum; 2006 Dec 15; 55(6):900-4. PubMed ID: 17139667
    [Abstract] [Full Text] [Related]

  • 7. Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares.
    Walz LeBlanc BA, Gladman DD, Urowitz MB.
    J Rheumatol; 1994 Dec 15; 21(12):2239-41. PubMed ID: 7699623
    [Abstract] [Full Text] [Related]

  • 8. Impaired phagocytosis of apoptotic cell material in serologically active clinically quiescent patients with systemic lupus erythematosis.
    Huang WN, Tso TK, Wu HC, Yang HF, Tsay GJ.
    Int J Rheum Dis; 2016 Dec 15; 19(12):1310-1316. PubMed ID: 26692544
    [Abstract] [Full Text] [Related]

  • 9. Phenotypic subgroup in serologically active clinically quiescent systemic lupus erythematosus: A cluster analysis based on CSTAR cohort.
    Ding Y, Zhou Y, Zhan F, Xu J, Duan X, Luo H, Zhao C, Yang M, Wu R, Wu L, Chen Z, Wei W, Huang C, Wu C, Zhang S, Jiang N, Xu D, Leng X, Wang Q, Tian X, Li M, Zeng X, Zhao J.
    Med; 2024 Oct 11; 5(10):1266-1274.e3. PubMed ID: 38991598
    [Abstract] [Full Text] [Related]

  • 10. Follow-up and management of serologically active clinically quiescent cases in pediatric systemic lupus erythematosus.
    Capone G, Lojacono C, Al-Bayitee F, Makvandi S, Hennon T, Wrotniak B, Abdul-Aziz R.
    Reumatologia; 2021 Oct 11; 59(4):244-251. PubMed ID: 34538955
    [Abstract] [Full Text] [Related]

  • 11. Clinically active serologically quiescent systemic lupus erythematosus.
    Gladman DD, Hirani N, Ibañez D, Urowitz MB.
    J Rheumatol; 2003 Sep 11; 30(9):1960-2. PubMed ID: 12966598
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
    Rose T, Grützkau A, Hirseland H, Huscher D, Dähnrich C, Dzionek A, Ozimkowski T, Schlumberger W, Enghard P, Radbruch A, Riemekasten G, Burmester GR, Hiepe F, Biesen R.
    Ann Rheum Dis; 2013 Oct 11; 72(10):1639-45. PubMed ID: 23117242
    [Abstract] [Full Text] [Related]

  • 14. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.
    Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, Gladman DD, Urowitz M, Fortin PR, Wither J.
    Ann Rheum Dis; 2009 Sep 11; 68(9):1440-6. PubMed ID: 18772188
    [Abstract] [Full Text] [Related]

  • 15. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK.
    Arthritis Rheum; 2005 May 11; 52(5):1491-503. PubMed ID: 15880830
    [Abstract] [Full Text] [Related]

  • 16. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study.
    Conti F, Ceccarelli F, Perricone C, Miranda F, Truglia S, Massaro L, Pacucci VA, Conti V, Bartosiewicz I, Spinelli FR, Alessandri C, Valesini G.
    PLoS One; 2012 May 11; 7(9):e45934. PubMed ID: 23029327
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
    Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM.
    Arthritis Rheum; 2009 Nov 11; 60(11):3436-46. PubMed ID: 19877033
    [Abstract] [Full Text] [Related]

  • 18. Cytokines in relation to autoantibodies before onset of symptoms for systemic lupus erythematosus.
    Eriksson C, Rantapää-Dahlqvist S.
    Lupus; 2014 Jun 11; 23(7):691-6. PubMed ID: 24531079
    [Abstract] [Full Text] [Related]

  • 19. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus.
    Ferreira GA, Teixeira AL, Sato EI.
    Lupus; 2010 Jul 11; 19(8):927-34. PubMed ID: 20410153
    [Abstract] [Full Text] [Related]

  • 20. Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus.
    Miyawaki Y, Sada K, Asano Y, Hayashi K, Yamamura Y, Hiramatsu S, Ohashi K, Morishita M, Watanabe H, Matsumoto Y, Kawabata T, Wada J.
    Lupus; 2018 Nov 11; 27(13):2093-2100. PubMed ID: 30309286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.